tbuckley/cabot-search huggingface dataset:
Smoking, exercise capacity and physical activity in daily life in physically independent elderly
Authors: Cristiane G. Gonçalves, Daniela Hayashi, Carolina L. Gonçalves, Denilson C. Teixeira, Eliane R.F.S. Freitas, Josiane M. Felcar, Vanessa S. Probst
Journal: European Respiratory Journal (2011)

Background: Smoking results in cardiovascular changes that can lead to a gradual decrease in exercise capacity and, when associated with the physiological changes related to the aging process, can decrease the physical performance of the elderly.

Objective: To investigate the relationship between smoking, exercise capacity and physical activity in daily life (PADL) in physically independent elderly.

Methods: Two hundred and nine physically independent elderly with normal lung function were assessed. They were distributed into four groups: smokers (SG; n=12; 6 women, 66 [64-71] yrs, BMI 24 [21-28] kg/m2), ex-smokers (ESG; n=63; 31 women, 69 [64-74] yrs, BMI 27 [25-31] kg/m2), passive smokers (PSG; n=42, 36 women; 66 [63-70] yrs, BMI 28 [25-31] kg/m2) and nonsmokers (NSG; n=92; 69 women, 67 [64-71] yrs, BMI 28 [24-32] kg/m2). Subjects were submitted to assessment of exercise capacity (6 minute walking test (6MWT) and the incremental shuttle walk test (ISWT)), PADL using a questionnaire (Baecke) and a step counter, as well as smoking habits.

Results: There was no statistically significant difference among groups regarding functional and maximal exercise capacity and PADL as seen in table 1.

View this table:

Table 1





Conclusion: Physically independent elderly with preserved lung function, smokers or not, seem to present similar pattern of exercise capacity and PADL.
Warfarin Anticoagulation and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction 11This study was supported by Grant MO1-RR00054 from the General Clinical Research Center, funded by the Division of Research Resources, National Institutes of Health, Bethesda, Maryland. The Studies of Left Ventricular Dysfunction (SOLVD) were funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, with a contribution from Merck, Sharpe …
Authors: Ayman S Al-Khadra, Deeb N Salem, William M Rand, James E Udelson, John J Smith, Marvin A Konstam
Journal: Journal of the American College of Cardiology (1998)
693. Retrovirally Transduced Bone Marrow Has Effect on Brain Pathology in Mouse Model of Mucopolysaccharidosis IIIB
Authors: Yi Zheng, Sergey Ryazantsev, Kazuhiro Ohmi, Huizhi Zhao, Nora Rozengurt, Donald B. Kohn, Elizabeth F. Neufeld
Journal: Molecular Therapy (2004)
Functional Somatic Syndromes
Authors: Melody Heard
Journal: Annals of Internal Medicine (2000)

Letters15 February 2000Functional Somatic SyndromesMelody HeardMelody HeardAmarillo, TX 79121 (Heard)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-4-200002150-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I have been to various doctors and specialists in numerous fields to determine my illness. After suffering for more than a year, receiving several misdiagnoses and undergoing extensive tests, I was finally given a diagnosis of chronic fatigue syndrome by a specialist in infectious diseases. That was more than 3 years ago.I have continually tried to disprove the chronic fatigue syndrome diagnosis by refusing to believe I have it and trying to continue my “normal” lifestyle. I remember hearing about this illness and thinking how horrible it would be to contract it. To this day, I ...Reference1. Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med. 1999;130:910-21. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Amarillo, TX 79121 (Heard) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFunctional Somatic Syndromes Arthur J. Barsky and Jonathan F. Borus Functional Somatic Syndromes Frank Albrecht Functional Somatic Syndromes Thomas L. English Functional Somatic Syndromes Thomas L. Kurt Functional Somatic Syndromes Arthur J. Barsky and Jonathan F. Borus Functional Somatic Syndromes Terry E. Hedrick Functional Somatic Syndromes James McSherry Functional Somatic Syndromes Kenneth Clemenger Functional Somatic Syndromes Allan Clemenger Functional Somatic Syndromes Ellen Goudsmit Metrics 15 February 2000Volume 132, Issue 4Page: 328KeywordsChronic fatigue syndromeHearingInfectious diseases ePublished: 15 August 2000 Issue Published: 15 February 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Prevalence of dermatoporosis in elderly French hospital in-patients: a cross-sectional study
Authors: V. Mengeaud, C. Dautezac-Vieu, G. Josse, B. Vellas, A.-M. Schmitt
Journal: British Journal of Dermatology (2011)

Funding sources: This work was supported by Pierre Fabre Group. Conflicts of interest: V.M., G.J. and A.M.S. are employed by Pierre Fabre Dermo Cosmetique. Madam, The term dermatoporosis has recently been proposed to describe the clinical signs and functional consequences of age‐related extreme skin fragility. Dr Kaya and Prof. Saurat1 coined this term by analogy with osteoporosis to designate skin failure and described four stages: I, extreme skin thinning, purpura and pseudoscars; II, skin lacerations resulting from minor traumas, in addition to the previous signs; III, larger and more numerous skin lacerations and delayed wound healing; and IV, advanced lesions with subcutaneous bleeding, leading to dissecting haematomas and, potentially, skin necrosis. However, the prevalence of dermatoporosis has not previously been evaluated. We report here the results of a cross‐sectional, observational study evaluating the prevalence of dermatoporosis in 202 patients aged 60 years and older, hospitalized in the Department of Geriatrics of Toulouse University Hospital. Clinical examinations of the skin on the forearms, hands or legs, including skin phototype determination2 and dermatoporosis staging,1 were performed by a single dermatologist.
Are epidermal defects the key initiating factors in the development of atopic dermatitis?
Authors: E. Simpson
Journal: British Journal of Dermatology (2010)

Journal Article Are epidermal defects the key initiating factors in the development of atopic dermatitis? Get access E. Simpson E. Simpson Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, U.S.A. E‐mail: simpsone@ohsu.edu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 6, 1 December 2010, Pages 1147–1148, https://doi.org/10.1111/j.1365-2133.2010.10115.x Published: 01 December 2010
Atrial fibrillation - an end to the epidemic?
Authors: John Camm
Journal: Circulation (2005)

A trial fibrillation (AF) is said to be an epidemic, 1 affecting 1% to 1.5% of the population.The arrhythmia presently costs approximately 1% of the health care budget in the United Kingdom and in France.The prevalence is increasing because the population is aging and many older people have survived potential cardiovascular tragedies, leaving them exposed to the more insidious effects of underlying cardiovascular disease.Atrial fibrillation is one result.Although the arrhythmia carries little direct hazard, the risk of thromboembolism is substantial and increases exponentially with age. 2 Warfarin, but not aspirin, virtually eliminates this risk but carries its own dangers, predominantly hemorrhage.It is difficult to manage therapy with warfarin: full compliance, routine anticoagulation checks, polypharmacy vigilance, alcohol temperance, a consistent dietary regimen and the good fortune not to be involved in any significant trauma are essential but not guaranteed.Only 60% of those who need this therapy are treated. 3ew anticoagulant strategies are necessary and seemed imminent until a direct thrombin inhibitor, 4 already available in parts of Europe for the reduction of postoperative venous thromboembolism, was refused approval by regulatory authorities for use in atrial fibrillation.However, almost every big pharmaceutical company is interested in this problem and it will not be long before the thromboembolic risks of AF can be effectively treated without the hazards and inconvenience of warfarin treatment.Antiarrhythmic therapies, particularly amiodarone, sotalol, propafenone and flecainide, are moderately effective at initially reducing the incidence of paroxysms or persistent bouts of AF.Eventually, however, the disease becomes unresponsive, tolerance develops or side effects accumulate.Other therapies are needed.First surgeons and then physicians isolated the arrhythmia triggers in the pulmonary veins from the remainder of atrial myocardium and prevented recurrence of AF.Although these techniques will help many, it is not yet clear how successful they will prove in the long-term.In any event, the application of such an expensive and technologically demanding procedure to the millions of those who suffer from AF seems unlikely to be realised.A pharmacological, and preferably a preventative strategy is needed to cope with an epidemic.Efforts to identify such a solution are hampered by our failure to fully understand the mechanism of AF.However, most of the disease seems to stem from other cardiac 'Atrial fibrillation -an end to the
Physician compensation, past and present
Authors: Renate G Justin
Journal: BMJ (2003)

From BMJ USA 2003;May:276 

Since earliest times, wise men have experimented with various methods of compensating physicians. Fee for service is the oldest documented model. The Code of Hammurabi (1792 - 1750 BC) specified physicians' fees: “If a doctor has healed a freeman's bone or has restored diseased flesh,… the patient shall give the doctor five shekels of silver.” The Mesopotamian rulers set the amount to be paid for each procedure, just as the Canadian government does today.

In 2000 BC, Egyptian physicians were salaried, employed by the army or the temple. They would not charge for services, only for the medication they dispensed. …
THE QUESTION OF HYPNOSIS IN MEDICAL PRACTICE
Authors: F G PLEUNE
Journal: Annals of Internal Medicine (1960)

Article1 June 1960THE QUESTION OF HYPNOSIS IN MEDICAL PRACTICEF. GORDON PLEUNE, M.D.F. GORDON PLEUNE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-52-6-1273 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA recent and widespread revival of interest in the use of hypnosis in medicine has aroused a strong and sincere desire on the part of many doctors for a clearer understanding of what hypnosis is, and when, how and for what it should or should not be used. This interest seems particularly strong among physicians who are not psychiatrists but who want to learn about using hypnosis in their medical practice. The question arises of using hypnosis not only for analgesia or anesthesia, but for a gamut of conditions like overeating, excessive drinking, excessive smoking, insomnia, vomiting, and in particular... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rochester, N. Y.*Received for publication January 4, 1960.From the Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, N. Y.Requests for reprints should be addressed to F. Gordon Pleune, M.D., 260 Crittenden Boulevard, Rochester 20, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1960Volume 52, Issue 6Page: 1273-1278KeywordsAnalgesiaAnesthesiaDentistryInsomniaVomiting ePublished: 1 December 2008 Issue Published: 1 June 1960 PDF downloadLoading ...
Inducible expression of interleukin-12 for the treatment of liver metastases using a high-capacity adenoviral vector
Authors: Ruben Hernandez-Alcoceba, Itsaso Mauleon, Maider Zabala, Vijay Shankar, Stefan Kochanek, Jesus Prieto, Cheng Qian
Journal: Molecular Therapy (2004)

Background and aims: The cytokine Interleukin-12 (IL-12) has a potent antitumor effect on a variety of cancer models, but its toxicity precludes the systemic administration in humans. The liver-directed expression of IL-12 using adenoviral vectors is a promising alternative for the treatment of primary and metastatic liver cancer. The development of a high-capacity (“gutless”) adenoviral vector with a mifepristone-inducible system for expression of IL-12 (GL-Ad/RUmIL12) can add further efficacy and safety to this approach. Here we describe the kinetics of IL-12 expression, the toxicity and the antitumor effect of GL-Ad/mIL12 on a newly developed tumor model using different routes of administration.
Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev
Authors: Thipparthi R. Reddy, Weidong Xu, Jonathan K. L. Mau, Christopher D. Goodwin, Modem Suhasini, Hengli Tang, Kenneth Frimpong, David W. Rose, Flossie Wong-Staal
Journal: Nature Medicine (1999)
Responsibility for public health should remain at health department.
Authors: Kiran Somani
Journal: BMJ (2001)

Public health should remain the responsibility of the Department of Health, said the secretary of state for health for England, Alan Milburn, said last week.

Mr Milburn was addressing the parliamentary health committee, which is undertaking an inquiry into public health. The minister for public health, Yvette Cooper, was also present.

Mr Milburn …
Corneal Sensation and Subbasal Nerve Alterations in Patients with Herpes Simplex Keratitis
Authors: Pedram Hamrah, Andrea Cruzat, Mohammad H. Dastjerdi, Lixin Zheng, Bashar M. Shahatit, Hasan A. Bayhan, Reza Dana, Deborah Pavan-Langston
Journal: Ophthalmology (2010)
Abstract 17861: Identification of Cardiovascular Lineage Descendants at Single Cell Resolution
Authors: Guang Li, Karolina Plonowska, Rajarajan Kuppusamy, Sean M. Wu
Journal: Circulation (2014)

BACKGROUND:  The transcriptional profile of cardiac cells derived from murine embryos and from mouse embryonic stem cells (mESCs) has primarily been studied as a cell population. However, the characterization of gene expression in these cells at a single cell level may demonstrate unique variations not appreciated as a pool.   METHODS AND RESULTS:  To establish a single cell quantitative PCR platform and perform side-by-side comparison between cardiac progenitors cells (CPCs) and cardiomyocytes (CMs) derived from our previously described Nkx2.5 enhancer-eGFP mESC and mouse embryos, we generated a reference map for single cardiovascular cells through quantifying lineage-defining genes for CPCs, CMs, smooth muscle cells (SMCs), endothelial cells (EDCs), fibroblasts, and mESCs using the Fluidigm microfluidic-enabled multiplex PCR assay. This panel was then applied against day 10.5 embryonic heart single cells to demonstrate its ability to identify chamber-specific CMs, endocardial cells, and fibroblasts. In addition, we compared the gene expression profiles of Nkx2.5 enhancer-eGFP embryo- and mESC-derived CPCs and CMs at different developmental stages and showed that single mESC-derived CM is transcriptionally similar to embryo-derived CM up to the neonatal stage. Furthermore, we show that time-lapse microscopy coupled with single cell expression assay can resolve the identity and the lineage relationship of progenies of single cultured CPC. With this approach, we found differential propensity for mESC-derived CPCs to become SMCs and CMs, whereas embryo-derived CPC to become CMs or EDCs.   CONCLUSIONS:  Our single cell expression profiling assays demonstrate the transcriptional similarity between mESC and embryo-derived CPC and CM up to the neonatal stage of development as well as differences in the propensity of CPCs to differentiate into cardiovascular cells. Single cell expression analysis appears to be a powerful tool to address the unique behavior of individual embryo- or mESC-derived cardiovascular cells.
Cryopreservation of neurospheres derived from malignant human glioma
Authors: Norazean Zaiden, Constance Chua, Szu Shien Ng, Yingjia Cai, SJ See, WH Ng, Ivan Ng, Beng-Ti Ang, Carol Tang
Journal: Clinical Cancer Research (2007)

AACR Centennial Conference: Translational Cancer Medicine-- Nov 4-8, 2007; Singapore

C1 

Cancer stem cells have been isolated from a variety of cancers as well as brain tumors. In this study, we develop a novel method of preserving brain tumor neurospheres in order to facilitate cryopreservation in investigative work. We focus on comparing cryopreservation results by vitrification or conventional slow-cooling methods. Isolated brain tumor neurospheres containing the tumor-initiating CD133-positive population from two glioblastoma multiforme (GBM) patients were cryopreserved. We demonstrate that vitrification yielded better viability upon thawing after long-term storage in liquid nitrogen, as well as maintained “stemness” properties exhibited by the neurospheres prior to cryopreservation as determined by real-time PCR and immunofluorescence studies. There was also no change in the multipotentiality of vitrified or non-vitrified neurospheres. The cytogenetic hallmarks of GBM neurospheres remained unaltered after vitrification, demonstrating that the cryopresevation method did not cause additional chromosomal abnormalities. Importantly, our vitrified tumor neurospheres when implanted in immune-compromised mice formed glioma xenografts that were phenocopies of the patients’ original tumors. These data support the use of the vitrification process in establishing a brain tumor neurosphere repository for facilitating further studies focused on this cellular sub-population.
Clinical Hematology and Fundamentals of Hemostasis
Authors: Denise M. Harmening
Journal: Annals of Internal Medicine (1992)

I. Introduction to Clinical Hematology Morphology of Human Blood and Marrow Cells: Hematopoiesis Bone Marrow The Red Blood Cell: Structure and Function Anemia: Diagnosis and Clinical Considerations Evaluation of Cell Morphology and Introduction to Platelet and White Cell Morphology II. Anemias Iron Metabolism and Hypochromic Anemias Megaloblastic Anemias Aplastic Anemia Including Pure Red Cell Aplasia and Congenital Dyserythropoietic Anemia and Paroxysmal Noctural Hemoglobinuria (PNH) Introduction to Hemolytic Anemias: Intracorpuscular Defects: I. Hereditary Defects of the Red Cell Membrane Hemolytic Anemias: Intracorpuscular Defects: II. Hereditary Enzyme Deficiencies Hemolytic Anemias: Intracorpuscular Defects: III. The Hemoglobinopathies Hemolytic Anemias: Intracorpuscular Defects: IV. Thalassemia Hemolytic Anemias: Extracorpuscular Defects Hypoproliferative Anemia: Anemia Associated with Systemic Diseases III. White Blood Cell Disorders Cell Biology, Disorders of Neutrophils, Infectious Mononucleosis, and Reactive Lymphocytosis Introduction to Leukemia and the Acute Leukemias Chronic Myeloproliferative Disorders: I. Chronic Myclogenous Leukemia Chronic Myeloproliferative Disorders: II. Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis Myelodysplastic Syndromes (MDS) chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders The Lymphomas Mutiple Myeloma and Related Plasma Cell Disoders Lipid (Lysosomal) Storage Diseases and Histiocytosis IV. Hemostasis and Introduction to Thrombosis Introduction to Hemostasis Disorders of Primary Hemostasis: Quantitative and Qualitative Platelet Disorders and Vascular Disorders Disorders of Plasma Clotting Factors Interaction of the Fibrinolytic, Coagulation, and Kinin Systems: Disseminated Intravascular Coagulation and Related Pathology Introduction to Thrombosis and Anticoagulant Therapy IV. Laboratory Methods Quality Control in the Hematology Laboratory Body Fluid Examination: The Qualitative, Quantitative, and Morphologic Analysis of Serous, Cerebrospinal, and Synovial Fluids Hematology Methods Principles of Automated Differential Analysis Coagulation Procedures Applications of Flow Cytometry to Hematology and Hemostasis Molecular Diagnostic Techniques in Hematopathology Special Stains/Cytochemistry Answers to Chapter Review Questions Glossary Bibliography
Abstract 3075: <i>Ex-vivo</i> expansion of circulating tumor cells in early lung cancer using a microfluidic model
Authors: Jennifer Zhuo Zhang, Hiroe Shiratsuchi, Jules Lin, Guoan Chen, Rishindra M. Reddy, Ebrahim Azizi, Shamileh Fouladdel, Andrew C. Chang, Lin Lin, Diane M. Simeone, Max S. Wicha, David G. Beer, Nithya Ramnath, Sunitha Nagrath
Journal: Cancer Research (2014)

Abstract Circulating tumor cells (CTCs) have gathered much momentum in recent times with emerging micro and nanotechnologies enabling better recoveries of these rare cells. Future research directions in CTCs significantly depend on obtaining meaningful number of CTCs that are available for downstream assays. This can be achieved by expanding CTCs. However, in early stage cancer patients, the numbers of cells that circulate in the peripheral blood are rare. Therefore until now, expanding CTCs remains to be a serious challenge limiting clinical utility. Microfluidic technologies have demonstrated that these rare cells can be recovered with better efficiency, purity and high viability. Herein, we developed a strategy using microfluidic technology to isolate and expand CTCs. We have successfully expanded CTCs isolated from 16 out of 21 early stage lung cancer patients. Expanded CTCs expressed tumor specific markers and formed spheroids in culture. Furthermore, these expanded CTCs carried the identical cancer related mutations (e.g. TP53 mutation) as their primary tumors. We expect that our model opens up the unprecedented avenues to understand biology of these lethal drivers of metastasis offering opportunities for personalized medicine through target drug evaluations. Citation Format: Jennifer Zhuo Zhang, Hiroe Shiratsuchi, Jules Lin, Guoan Chen, Rishindra M. Reddy, Ebrahim Azizi, Shamileh Fouladdel, Andrew C. Chang, Lin Lin, Diane M. Simeone, Max S. Wicha, David G. Beer, Nithya Ramnath, Sunitha Nagrath. Ex-vivo expansion of circulating tumor cells in early lung cancer using a microfluidic model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3075. doi:10.1158/1538-7445.AM2014-3075